United States - English - NLM (National Library of Medicine)

galderma laboratories, l.p. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 1 mg in 1 mg - capex® shampoo is a low to medium potency corticosteroid indicated for the treatment of seborrheic dermatitis of the scalp. this product has not been proven to be effective in other corticosteroid-responsive dermatoses. capex® shampoo is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

royal pharmaceuticals - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 1 ml - dermotic® oil is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

specialised therapeutics alim pty ltd - fluocinolone acetonide, quantity: 190 microgram - implant - excipient ingredients: polyvinyl alcohol; pmda/oda copolymer; dimeticonol; ethyltriacetoxysilane; methyltriacetoxysilane; dibutyltin diacetate; silica dimethicone silylate - iluvien is indicated for the treatment of diabetic macular oedema (dme) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (iop).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide topical oil, 0.01% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section). pediatric use: fluocinolone acetonide topical oil, 0.01% may be used twice daily for up to 4 weeks in pediatric patients 2 years and older with moderate to severe atopic dermatitis.  fluocinolone acetonide topical oil, 0.01% should not be applied to the diaper area. application to intertriginous areas should be avoided due to the increased possibility of local adverse events such as striae, atrophy, and telangiectasia, which may be irreversible. the smallest amount of drug needed to cover the affected areas should be applied. long term safety in the pediatric population has not been established. fluocinolone acetonide topical oil, 0.01% is not recommended for use on the face (see adverse reactions section). because of a higher ratio of skin surface area to body mass, children are at

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u), fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - ciprofloxacin and fluocinolone acetonide otic solution is indicated for the treatment of acute otitis media with tympanostomy tubes (aomt) in pediatric patients (aged 6 months and older) due to staphylococcus aureus , streptococcus pneumoniae , haemophilus influenzae , moraxella catarrhalis , and pseudomonas aeruginosa . ciprofloxacin and fluocinolone acetonide otic solution is contraindicated in: - patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of ciprofloxacin and fluocinolone acetonide otic solution. - viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. risk summary ciprofloxacin and fluocinolone acetonide otic solution is negligibly absorbed following otic administration and maternal use is not expected to result in fetal exposure to ciprofloxacin and fluocinolone acetonide [see clinical pharmacology (12.3)]. risk summary ciprofloxaci

United States - English - NLM (National Library of Medicine)

xspire pharma, llc - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u), fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - ciprofloxacin and fluocinolone acetonide otic solution is indicated for the treatment of acute otitis media with tympanostomy tubes (aomt) in pediatric patients (aged 6 months and older) due to staphylococcus aureus , streptococcus pneumoniae , haemophilus influenzae , moraxella catarrhalis , and pseudomonas aeruginosa . ciprofloxacin and fluocinolone acetonide otic solution is contraindicated in: - patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of ciprofloxacin and fluocinolone acetonide otic solution. - viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. risk summary ciprofloxacin and fluocinolone acetonide otic solution is negligibly absorbed following otic administration and maternal use is not expected to

United States - English - NLM (National Library of Medicine)

royal pharmaceuticals - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 1 ml - derma-smoothe/fs® is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section). derma-smoothe/fs® may be used twice daily for up to 4 weeks in pediatric patients 2 years and older with moderate to severe atopic dermatitis. derma-smoothe/fs® should not be applied to the diaper area. application to intertriginous areas should be avoided due to the increased possibility of local adverse events such as striae, atrophy, and telangiectasia, which may be irreversible. the smallest amount of drug needed to cover the affected areas should be applied. long term safety in the pediatric population has not been established. derma-smoothe/fs® is not recommended for use on the face (see adverse reactions section). because of a higher ratio of skin surface area to body mass, children are at a greater risk than adults of hpa-axis-suppression when they are treated with topical corticosteroids. they are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of cushing's syndrome while on treatment. adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. (see precautions). hpa axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. derma-smoothe/fs® is formulated with 48% refined peanut oil nf. peanut oil used in this product is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million (ppm). physicians should use caution in prescribing derma-smoothe/fs® for peanut sensitive individuals.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 1 ml - derma-smoothe/fs® is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section).

United States - English - NLM (National Library of Medicine)

patrin pharma, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide oil, 0.01% is a low to medium potency corticosteroid indicated for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and older. fluocinolone acetonide oil, 0.01% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions).

Philippines - English - FDA (Food And Drug Administration)

euro-med laboratories phil., inc. - fluocinolone acetonide - cream - each g contains 250 mcg fluocinolone acetonide